Skip to main content
Premium Trial:

Request an Annual Quote

Cell Signaling Technology and LI-COR to Validate, Co-Market Cellular Assays

NEW YORK, June 1 (GenomeWeb News) - Cell Signaling Technology and LI-COR Biosciences said today that they have signed a joint marketing and validation agreement for CST's antibody reagents used with LI-COR's cellular assays.


The companies said they will validate LI-COR's In-Cell Western cellular imaging assays with CST's phospho-specific antibodies, which target signaling molecules such as kinases and apoptosis regulators. The firms plan to develop a set of validated assays for therapeutically relevant signaling pathway proteins that will allow customers to measure phosphorylation of these proteins in the cell.


The companies will validate the assays on LI-COR's Odyssey infrared imaging system.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.